


## CORRECTION



# Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF<sup>V600</sup>-mutant advanced melanoma patients: a propensity-matched survival analysis

Jesper van Breeschoten, Michel W. J. M. Wouters, Doranne L. Hilarius, John B. Haanen, Christian U. Blank, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Jan-Willem B. de Groot, Geke A. P. Hospers, Ellen Kapiteijn, Djura Piersma, Roos S. van Rijn, Karijn P. M. Suijkerbuijk, Willeke A. M. Blokx, Bert-Jan J. ten Tije, Astrid A. M. van der Veldt , Art Vreugdenhil, Marye J. Boers-Sonderen and Alfonsus J. M. van den Eertwegh

© The Author(s), under exclusive licence to Springer Nature Limited 2022

*British Journal of Cancer* (2022) 126:1362; <https://doi.org/10.1038/s41416-022-01772-z>

Correction to: *British Journal of Cancer* <https://doi.org/10.1038/s41416-020-01229-1>, published online 26 January 2021

The original version of this article unfortunately contained a mistake. During online publication of this article an incorrect notification was included by the Publisher in the Additional

Information. The notification incorrectly stated that the licence terms for these articles would switch to a Creative Commons Attribution 4.0 International (CC BY 4.0) after a period of 12 months. This notification has been removed and the articles have been updated.